Liquidia Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
216
- Stock Symbol
-
LQDA
- Share Price
-
$57.42
- (As of Friday Closing)
Liquidia General Information
Description
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Contact Information
Website
www.liquidia.comCorporate Office
- 419 Davis Drive
- Suite 100
- Morrisville, NC 27560
- United States
Corporate Office
- 419 Davis Drive
- Suite 100
- Morrisville, NC 27560
- United States
Liquidia Timeline
Liquidia Stock Performance
As of 13-Nov-2026, Liquidia’s stock price is $57.42. Its current market cap is $5.17B with 90.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $57.42 | $58.12 | $22.31 - $93.61 | $5.17B | 90.1M | 3.49M | -$1.05 |
Liquidia Financials Summary
As of 30-Sep-2026, Liquidia has a trailing 12-month revenue of $622M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,607,254 | 3,042,160 | 793,650 | 752,041 |
| Revenue | 621,865 | 158,320 | 13,996 | 17,488 |
| EBITDA | (94,949) | (49,848) | (119,097) | (73,517) |
| Net Income | (94,189) | (68,924) | (128,291) | (78,502) |
| Total Assets | 682,942 | 327,934 | 230,313 | 118,332 |
| Total Debt | 168,758 | 197,927 | 120,287 | 49,536 |
Liquidia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Liquidia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Liquidia Comparisons
Industry
Financing
Details
Liquidia Competitors (71)
One of Liquidia’s 71 competitors is EyePoint, a Corporation company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| EyePoint | Corporation | Watertown, MA | ||||
| Pacira BioSciences | Formerly VC-backed | Tampa, FL | ||||
| Agile Therapeutics | Formerly VC-backed | Princeton, NJ | ||||
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ | ||||
| Dalton Pharma Services | Corporate Backed or Acquired | Toronto, Canada |
Liquidia Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Liquidia Patents
Liquidia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161676-A1 | Booster therapy for treating or preventing exacerbations of pulmonary hypertension symptoms | Pending | 24-Jan-2025 | ||
| WO-2026107295-A1 | Combination therapy for the treatment of pulmonary hypertension | Pending | 15-Nov-2024 | ||
| AU-2017261317-A1 | Dry powder treprostinil for the treatment of pulmonary hypertension | Inactive | 05-May-2016 | ||
| AU-2023201307-A1 | Dry powder treprostinil for the treatment of pulmonary hypertension | Inactive | 05-May-2016 | ||
| AU-2025204321-A1 | Dry powder treprostinil for the treatment of pulmonary hypertension | Pending | 05-May-2016 | A61K31/557 |
Liquidia Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Liquidia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Liquidia ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.8 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Liquidia FAQs
-
When was Liquidia founded?
Liquidia was founded in 2004.
-
Where is Liquidia headquartered?
Liquidia is headquartered in Morrisville, NC.
-
What is the size of Liquidia?
Liquidia has 216 total employees.
-
What industry is Liquidia in?
Liquidia’s primary industry is Pharmaceuticals.
-
Is Liquidia a private or public company?
Liquidia is a Public company.
-
What is Liquidia’s stock symbol?
The ticker symbol for Liquidia is LQDA.
-
What is the current stock price of Liquidia?
As of 13-Nov-2026 the stock price of Liquidia is $57.42.
-
What is the current market cap of Liquidia?
The current market capitalization of Liquidia is $5.17B.
-
What is Liquidia’s current revenue?
The trailing twelve month revenue for Liquidia is $622M.
-
Who are Liquidia’s competitors?
EyePoint, Pacira BioSciences, Agile Therapeutics, Johnson&Johnson Innovative Medicine, and Dalton Pharma Services are some of the 71 competitors of Liquidia.
-
What is Liquidia’s annual earnings per share (EPS)?
Liquidia’s EPS for 12 months was -$1.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
